Refractory Acute Myeloid Leukemia Clinical Trials in Nashville, Tennessee

3 studies are recruiting for refractory acute myeloid leukemia in Nashville, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

    This is a first in human, multi center, open label, phase 1/1b study to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory (R/R), measurable residual disease (MRD) positive acute myeloid leukemia (AML), or TP53mut disease.

    Stage
    Phase 1
    Ages
    18 to 85
    Site
    Sarah Cannon Research Insitute, Nashville, Tennessee
    Locations
    5 in total
    Run by
    CERo Therapeutics Holdings, Inc.

    See if you can join NCT06834282 on ClinicalTrials.gov

  2. Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

    This phase I trial tests the safety, side effects, and best dose of eltanexor in combination with venetoclax for the treatment of patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has come back after a period of improvement (relapsed) or that has not responded to pre…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
    Locations
    2 in total
    Run by
    Vanderbilt-Ingram Cancer Center

    See if you can join NCT06399640 on ClinicalTrials.gov

  3. A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

    Study BH-30236-01 is a first-in-human (FIH), Phase 1/1b, open-label, dose escalation and expansion study in participants with relapsed/refractory acute myelogenous leukemia (R/R AML) or higher-risk myelodysplastic syndrome (HR-MDS). Phase 1, Part 1 Dose Escalation - Monotherapy will evaluate the sa…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Sarah Cannon Research Institute, Nashville, Tennessee
    Locations
    13 in total
    Run by
    BlossomHill Therapeutics

    See if you can join NCT06501196 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.